Do “Dear Health Care Professional” Letters Make a Difference?

Abstract

View all access options for this article.

Hazlet

T.K.

, Lee

T.A.

, Hansten

P.D.

Performance of community pharmacy drug interaction software. J Am Pharm Assoc. 2001; 41(2): 200–4.

Smalley

, Shatin

, Wysowski

D.K.

Contraindicated use of cisapride: Impact of Food and Drug Administration regulatory action. JAMA. 2000; 284(23): 3036–9.

Carlson

A.M.

, Morris

L.S.

Co-prescription of terfenadine and erythromycin or keto-conazole: | An assessment of potential harm. J Am Pharm Assoc. 1996; NS36(4): 263–9.